Skip to main content

CTOS 2025 Main banner

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

A
P 188
A CALCULATOR TO ESTIMATE EFFECTIVE IMATINIB CONCENTRATIONS IN GIST AFTER ADJUSTING FOR PROTEIN BINDING

Favorite
P 160
A COMPARATIVE ANALYSIS OF DEDIFFERENTIATED AND CONVENTIONAL CHONDROSARCOMA OUTCOMES

Favorite
P 91
A COMPARISON OF ACETABULAR AUGMENTATION AND PHOTODYNAMIC NAIL STABILIZATION FOR COMPLEX ONCOLOGIC TOTAL HIP ARTHROPLASTY

Favorite
P 116
A DUAL-TARGETED SYSTEMIC THERAPEUTIC APPROACH FOR THE SELECTIVE ELIMINATION OF TUMOR CELLS IN PRIMARY AND METASTATIC SARCOMA.

Favorite
P 434
A FIRST-IN-HUMAN PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF M3554, A NOVEL ANTI-GD2 ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH ADVANCED SOLID TUMORS

Favorite
P 311
A FOLLOW-UP STUDY ON THE NOVEL USE OF CONTRAST-ENHANCED SUSCEPTIBILITY-WEIGHTED IMAGING FOR EXTREMITY DESMOID FIBROMATOSIS RESPONSE ASSESSMENT

Favorite
P 07
A LIVING MULTI-OMICS BIOBANK OF PATIENT-DERIVED XENOGRAFT MODELS FOR SARCOMA

Favorite
P 84
A MULTICENTER COMPARISON OF REVERSE TOTAL SHOULDER ARTHROPLASTY VERSUS HEMIARTHROPLASTY FOR ENDOPROSTHETIC RECONSTRUCTION FOLLOWING ONCOLOGIC RESECTION OF THE PROXIMAL HUMERUS

Favorite
P 138
A MULTI-INSTITUTIONAL ARCHIVE AND DEEP LEARNING PIPELINE FOR QUANTIFYING CHONDROSARCOMA COMPOSITION

Favorite
P 50
A NEW MURINE MODEL OF DEDIFFERENTIATED LIPOSARCOMA DEFINED BY HIGH PROLIFERATION AND METABOLIC ADAPTABILITY

Favorite
P 430
A PH/2 STUDY OF THE RADIOPHARMACEUTICAL [AC-225]RTX-2358 IN THE TREATMENT OF RELAPSED / REFRACTORY (R/R) SOFT TISSUE SARCOMA (STS) THE ATLAS STUDY - ACTINIUM THERAPY FOR LATE-STAGE AGGRESSIVE SARCOMAS

Favorite
P 287
A PHASE 1 STUDY OF NEOADJUVANT CABOZANTINIB IN COMBINATION WITH RADIATION THERAPY FOR SARCOMAS OF THE EXTREMITIES

Favorite
P 415
A PHASE 1/2 TRIAL OF FOG-001, A FIRST-IN-CLASS DIRECT β-CATENIN:TCF4 INHIBITOR: SAFETY AND PRELIMINARY ANTITUMOR ACTIVITY IN PATIENTS WITH DESMOID TUMORS (DT)

Favorite
P 416
A PHASE 2 MULTICENTER OPEN-LABEL BASKET STUDY OF TAZEMETOSTAT IN ADULT PATIENTS WITH INI1-NEGATIVE EPITHELIOID SARCOMA – FINAL ANALYSIS

Favorite
P 426
A PHASE I/II TRIAL USING RNA LIPID NANOPARTICLES FOR RECURRENT OSTEOSARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION

Favorite
P 435
A PHASE II STUDY OF HIGH DOSE IFOSFAMIDE IN METASTATIC/LOCALLY ADVANCED SYNOVIAL SARCOMA FROM A TERTIARY CARE CENTER IN INDIA

Favorite
P 461
A RETROSPECTIVE ANALYSIS OF PATIENTS WITH CONVENTIONAL CHORDOMA TREATED WITH SYSTEMIC THERAPY

Favorite
P 141
A RETROSPECTIVE ANALYSIS OF THE BIRMINGHAM ATYPICAL CARTILAGE TUMOUR IMAGING PROTOCOL (BACTIP) IN MANAGING CENTRAL CARTILAGE TUMORS OF THE LONG BONES

Favorite
P 457
A RETROSPECTIVE REVIEW OF LOW-GRADE FIBROMYXOID SARCOMA: SURGICAL MANAGEMENT, RADIATION THERAPY, AND OUTCOMES

Favorite
P 44
A SYSTEMATIC REVIEW OF FUSION-DRIVEN SARCOMAS

Favorite
P 183
ACTIONABLE GENOMICS IN GASTROINTESTINAL STROMAL TUMORS LACKING KIT OR PDGFRA MUTATIONS.

Favorite
P 87
ACUTE PATHOLOGICAL LONG BONE FRACTURES: WEEKEND VERSUS WEEKDAY VARIATIONS AND THEIR CLINICAL IMPACT

Favorite
P 367
ADHERENCE TO GERMAN SARCOMA GUIDELINE FOR MRI SEQUENCING IN SOFT TISSUE SARCOMA: EVALUATION OF IMAGING PRACTICES AND COMPLIANCE

Favorite
P 28
ADVANCING PRECISION ONCOLOGY IN SOFT TISSUE SARCOMAS: THE ROLE OF ITRAC IN METASTATIC RISK STRATIFICATION AND TREATMENT PERSONALIZATION

Favorite
P 79
AGE-BASED TREATMENT PATTERNS AND OUTCOMES OF LOCALIZED HIGH-GRADE OSTEOSARCOMA FROM A NATIONWIDE DATABASE: WHAT IS THE OPTIMAL STRATEGY FOR PATIENTS OLDER THAN 40 YEARS?

Favorite
P 235
AGNOSTIC INDICATION OF IMMUNE CHECKPOINT INHIBITORS (ICI): PATTERNS OF RESPONSE OF SARCOMAS

Favorite
P 96
AMPUTATION FOLLOWING MEGAPROSTHESIS USE IN LIMB SALVAGE

Favorite
P 189
AN ALGORITHM TO PERSONALIZE IMATINIB PLASMA TESTING AND DOSE DECISIONS IN GIST PATIENTS

Favorite
P 248
AN EX VIVO ASSAY TO PREDICT IMMUNOTHERAPY RESPONSE IN SARCOMA

Favorite
P 127
AN INTEGRATED CLINICAL GENOMIC AND TRANSCRIPTOMIC SUBGROUPING OF CENTRAL CHONDROSARCOMA

Favorite
P 314
AN INTERNATIONAL, MULTI-CENTRE STUDY OF SURGICAL MARGINS IN INTERMEDIATE TO HIGH GRADE SARCOMA

Favorite
P 439
AN OPEN LABEL MULTICENTER PHASE 2 STUDY WITH SAFETY LEAD IN OF INTRATUMORAL VUSOLIMOGENE ODERPAREPVEC IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANGIOSARCOMA

Favorite
P 424
AN OPEN-LABEL PHASE 1/2 STUDY OF DCC-3009 MONOTHERAPY IN PATIENTS (PTS) WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST)

Favorite
P 255
AN OPEN-LABEL, TWO-COHORT, PHASE 1A/B STUDY OF WEEKLY IRINOTECAN HYDROCHLORIDE LIPOSOME INJECTION COMBINED WITH VINCRISTINE AND TEMOZOLOMIDE (NALIRI-VT) IN PATIENTS WITH ADVANCED EWING SARCOMA

Favorite
P 315
ANALYSIS OF CHANGES IN T2-WEIGHTED SIGNAL INTENSITY AND TUMOR VOLUME AND EXPOSURE-RESPONSE IN THE RINGSIDE PHASE 2 STUDY OF VAREGACESTAT FOR DESMOID TUMORS

Favorite
P 297
ANALYSIS OF CTDNA KINETICS IN PATIENTS WITH METASTATIC LEIOMYOSARCOMA UNDERGOING LOCOREGIONAL PROCEDURAL INTERVENTION

Favorite
P 204
ANALYSIS OF QUALITY INDICATORS OF SOFT TISSUE SARCOMA TREATMENT WITH CANCER REGISTRY DATA IN GERMANY 2015-2021

Favorite
P 29
ANTI-TUMOR ACTIVITY OF MICVOTABART PELIDOTIN IS ASSOCIATED WITH ENZYME GENE EXPRESSION IN PATIENT-DERIVED XENOGRAFT SARCOMA MODELS

Favorite
P 312
APOSST: A PROSPECTIVE TRIAL TO EVALUATE ACUPUNCTURE AFTER SURGERY OF EXTREMITY SOFT TISSUE TUMORS

Favorite
P 142
ARE THERE INDEPENDENT PREDICTORS OF DEDIFFERENTIATED CHONDROSARCOMA ON MAGNETIC RESONANCE IMAGING? A MULTIVARIATE ANALYSIS

Favorite
P 316
AREA DEPRIVATION INDEX (ADI) AND OUTCOMES IN LOCALIZED SOFT TISSUE SARCOMA: DO SOCIAL DETERMINANTS INFLUENCE SURVIVAL?

Favorite
P 66
ARHGEF4 EXPRESSION IN SOFT TISSUE SARCOMA CORRELATES WITH LOCAL GROWTH PATTERN: WHOLE TRANSCRIPTOME SEQUENCING ON SPATIALLY SEPARATED REGIONS, PATIENT-DERIVED MODELS, AND ORTHOTOPIC IN VIVO ANALYSIS

Favorite
P 81
ASSESSING PROGNOSTIC FACTORS OF CAUSE-SPECIFIC SURVIVAL IN PATIENTS WITH MALIGNANT GIANT CELL TUMORS: A POPULATION BASED STUDY FROM THE SEER DATABASE

Favorite
P 113
ASSESSING TREATMENT OUTCOMES OF CHONDROMYXOID FIBROMA: A CASE SERIES

Favorite
P 368
ASSESSMENT OF PAIN DIAGNOSIS AND PAIN MEDICATION USE IN ADULTS TREATED WITH NIROGACESTAT: A UNITED STATES REAL-WORLD ANALYSIS

Favorite
P 64
ATRX EXPRESSION CORRELATES WITH REDUCED IMMUNE CHECKPOINT EXPRESSION AND POOR SURVIVAL IN HIGH-RISK SOFT TISSUE SARCOMAS

Favorite
P 391
ATRX LOSS BLOCKS THE DIFFERENTIATION OF MESENCHYMAL STEM CELLS AND ADVANCES UNDIFFERENTIATED SARCOMA DEVELOPMENT

Favorite
P 310
ATYPICAL SPINDLE CELL PLEOMORPHIC LIPOMATOUS TUMORS OF THE RETROPERITONEUM ARE HETEROGENOUS: A REPORT OF FOUR DISPARATE CASES

Favorite